| Literature DB >> 36119658 |
Erminia Ridolo1,2, Francesco Pucciarini2, Paola Kihlgren3, Alessandro Barone2, Francesca Nicoletta2, Silvia Peveri3, Marcello Montagni3, Cristoforo Incorvaia4.
Abstract
Introduction: Lipid transfer proteins (nsLTPs) are ubiquitous allergens. Patients affected by nsLTP syndrome experience symptoms to various plant-derived foods, ranging from local manifestations to anaphylaxis, the critical treatment of which is represented by self-administration of adrenaline. The principle aim of this study is to assess how dietary recommendations influence the occurrence of new and severe cases and if poly-sensitization to different nsLTPs may play a role. We also investigated about the appropriate use of adrenaline auto-injector during the episodes of anaphylaxis. Moreover, we examinated how other features (ie, co-sensitization to profilin and PR-10 and the presence of risk co-factors) affect these events. Materials and methods: We evaluated 78 patients allergic to nsLTPs, investigating adherence to diet and ability to use the adrenaline auto-injector. Number of sensitization to nsLTPs, co-sensitization to other panallergens, and presence of risk factors for new reactions were also assessed. Diagnosis was based on clinical history and positivity to in vivo and in vitro tests. During the follow-up, compliance, diet modifications, and new reactions were noted, and re-training for the use of epinephrine auto-injector was performed. At the last visit we evaluated the patients' ability to use the self-injector.Entities:
Keywords: Adrenaline self-injector; Anaphylaxis; Co-factors; Food allergy; LTP syndrome
Year: 2022 PMID: 36119658 PMCID: PMC9468585 DOI: 10.1016/j.waojou.2022.100683
Source DB: PubMed Journal: World Allergy Organ J ISSN: 1939-4551 Impact factor: 5.516
Demographic and clinical characteristic of the patients.
| 27 | 51 | ||||
| 54 years | |||||
| Number of patients | 23% | Number of patients | 8% | ||
| ACE-inhibitors 2 | 2,5% | ||||
| Beta-blockers 4 | 5% | ||||
| 11 (14%) | 12 (15%) | 25 (32%) | 23 (30%) | 7 (9%) | |
| Number of patients | |||||
| 22 | 28% | ||||
| Walnut | 13 | 17% | |||
| Peanut | 13 | 17% | |||
| Hazelnut | 8 | 10% | |||
| Wheat | 2 | 3% | |||
| Other foods | 20 | 25% | |||
| Number of patients | Number of patients | ||||
| OAS | 4 | 6% | Urticaria/angioedema | 37 | 47% |
| Contact urticaria | 1 | 1% | Anaphylaxis | 31 | 40% |
| Isolated gastrointestinal symptoms | 1 | 1% | Anaphylactic shock | 4 | 5% |
| Number of patients | |||||
| Exercise | 8 | 10% | |||
| NSAIDs | 6 | 8% | |||
| Alcohol | 4 | 5% | |||
| Menstrual cycle | 1 | 1% | |||
| Fasting | 0 | 0% | |||
Clinical presentation of the first reaction, culprit food and eventual co-factors. Abbreviations: nsLTPs, non-specific lipid transfer proteins; OAS, oral-allergic syndrome; NSAIDs, non-steroidal anti-inflammatory drugs.
One patient reported the co-occurrence of two co-factors: menstrual cycle and use of NSAID.
Characteristics of the 29 patients who experienced new reactions during the follow-up period: clinical symptoms, culprit food, number of new reactions, co-factors, emergency department access and title of the positive IgEs (negative ones were not reported).
| Symptoms | Number of reactions | Culprit food | Use of self-injector | Emergency department? | Co-factor | Same food or not? | Positive IgEs title [kU/l] | |
|---|---|---|---|---|---|---|---|---|
| 1 | OAS | 1 | Cherry | No | No | No | No, but the same family | Ara h9 0.12 |
| 2 | Anaphylaxis | 1 | Cherry | No | No | No | No, but the same family. | Ara h9 3.76 |
| 3 | Urticaria/Angioedema | 1 | Chocolate with hazelnut | No | No | No | Ara h9 1.63 | |
| 4 | Anaphylaxis | 2 | Walnut, carrot | No | Yes (walnut) | Ara h9 1.52 | ||
| 5 | Anaphylaxis | 1 | Hazelnut | No | No | No | No, but the same family | Ara h9 0.16 |
| 6 | Urticaria/Angioedema | 2 | Persimmon | No | No | Ara h9 0.11 | ||
| 7 | Anaphylaxis | 1 | Melon | No | No | No | No | Ara h9 1.42 |
| 8 | Anaphylaxis | Multiple | Rosaceae, berries, grapes | No | No | No | No | Ara h9 1.80 |
| 9 | Anaphylaxis | 1 | Lupin bean | No | Yes | No | No | Ara h9 0.53 |
| 10 | Nausea, vomiting | 1 | Hazelnut | No | No | No | No, but the same family | Cor a8 1.96 |
| 11 | Urticaria/Angioedema | 3 | Kiwi, plum, Strawberry | No | No | No | Pru p3 11.90 | |
| 12 | Anaphylaxis | 1 | Corn | No | No | No | Ara h9 5.24 | |
| 13 | Anaphylactic shock | 1 | Wheat | No, ma praticata dal MET | Yes | No | No | Ara h9 14.71 |
| 14 | Anaphylaxis | 1 | Cherry | No | No | No | No | Ara h9 3.09 |
| 15 | Anaphylaxis, OAS | 2 | Peach, fennel | No | No | No | No | Ara h9 4.01 |
| 16 | Anaphylaxis | Multiple | Grapes, apple, hazelnut, almond | No | No | No | Ara h9 5.02 | |
| 17 | Anaphylaxis | 1 | Wheat | Yes | No | No | Ara h9 0.57 | |
| 18 | Anaphylaxis | 1 | Lettuce | No | No | No | No | Jug r3 1.21 |
| 19 | Anaphylaxis | 1 | Almond | No | No | No | No | Ara h9 6.12 |
| 20 | Anaphylactic shock | 1 | Hazelnut | No | Yes | No | Yes | Ara h9 7.02 |
| 21 | Anaphylaxis | 1 | Tree nuts mix | No | No | Yes | Ara h9 0.81 | |
| 22 | Anaphylaxis | 1 | Walnut | No | Yes | No | Yes | Ara h9 1.23 |
| 23 | Anaphylaxis | 1 | Fig | No | Yes | No | No | Ara h9 0.8 |
| 24 | Anaphylaxis | 1 | Corn | No | Yes | No | No | Ara h9 3.01 |
| 25 | Anaphylaxis | 1 | Apple | No | No | No | Yes | Jug r3 2.32 |
| 26 | Urticaria/angioedema | 2 | Hazelnut | No | Yes | No | No | Ara h9 1.09 |
| 27 | OAS | 1 | Walnut | No | No | No | Yes | Jug r3 3.01 |
| 28 | Urticaria/angioedema | 1 | Grapes | No | No | No | Ara h9 1.09 | |
| 29 | Urticaria/angioedema | 1 | Corn | No | No | No | Ara h9 2.05 |
Abbreviations: Ara h9, peanut-LTP; Jug r3, walnut-LTP; Pru p3, peach-LTP; Cor a8, almond-LTP; Tri a 14, wheat-LTP
Evaluation of patients’ ability to use the auto-injector
| Number of patients | ||
| No error | 37 | 47% |
| One to three errors | 38 | 49% |
| Four errors | 3 | 4% |
| Number of patients | ||
| Did not pull the safety cap | 15 | 19% |
| Incorrect handle of the device | 17 | 22% |
| Wrong site of injection | 27 | 35% |
| Holding the auto-injector in site for less than 10 s | 30 | 38% |